The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial

Study limitation reported by the research below: “This is a prespecified interim analysis at 12 weeks of a 48-week ongoing trial; histologic outcomes (fibrosis, MASH resolution) have not been reported.”